Prevalence and nature of statin drug-drug interactions in a university hospital by electronic health record mining
Our aim was to describe prevalence, nature, and level of severity of potential statin drug-drug interactions in a university hospital.
In a cross-sectional study, statin drug-drug interactions were screened from medical record of 10,506 in-patients treated stored in the clinical data warehouse “eHOP.” We screened drug-drug interactions using Theriaque and Micromedex drug databases.
A total of 22.5% of patients were exposed to at least one statin drug-drug interaction. Given their lipophilicity and CYP3A4 metabolic pathway, atorvastatin and simvastatin presented a higher prevalence of drug-drug interactions while fluvastatin presented the lowest prevalence. Up to 1% of the patients was exposed to a contraindicated drug-drug interaction, the most frequent drug-drug interaction involving influx-transporter (i.e., OATP1B1) interactions between simvastatin or rosuvastatin with cyclosporin. The second most frequent contraindicated drug-drug interaction involved CYP3A4 interaction between atorvastatin or simvastatin with either posaconazole or erythromycin. Furthermore, our analysis showed some discrepancies between Theriaque and Micromedex in the prevalence and the nature of drug-drug interactions.
Different drug-drug interaction profiles were observed between statins with a higher prevalence of CYP3A4-based interactions for lipophilic statins. Analyzing the three most frequent DDIs, the more significant DDIs (level 1: contraindication) were reported for transporter-based DDI involving OATP1B1 influx transporter. These points are of concern to improve prescriptions of statins.
KeywordsStatins Pharmacokinetics Drug-drug interactions Metabolic enzymes Drug transporters Drug databases Data mining Clinical data warehouse
Compliance with ethical standards
The ethics comitee of our institution approved the study with a waiver of patient consent authorization (number 17.60). Since the design of the study is retrospective no formal consent is required.
- 1.Gu Q, Paulose-Ram R, Burt VL, Kit BK (2014) Prescription cholesterol-lowering medication use in adults aged 40 and over: United States, 2003-2012. NCHS Data Brief 177:1–8Google Scholar
- 2.ANSM: Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cited 2017May 17]. Available from:http://www.ansm.sante.fr/searchengine/detail/(cis)/69358900/(limit)/90
- 5.Stewart D, Mair A, Wilson M, Kardas P, Lewek P, Alonso A, McIntosh J, MacLure K, SIMPATHY consortium (2017) Guidance to manage inappropriate polypharmacy in older people: systematic review and future developments. Expert Opin Drug Saf 16(2):203–213. https://doi.org/10.1080/14740338.2017.1265503 PubMedGoogle Scholar
- 7.Egger SS, Rätz Bravo AE, Hess L, Schlienger RG, Krähenbühl S (2007) Age-related differences in the prevalence of potential drug-drug interactions in ambulatory dyslipidaemic patients treated with statins. Drugs Aging 24(5):429–440. https://doi.org/10.2165/00002512-200724050-00006 CrossRefPubMedGoogle Scholar
- 9.Thériaque [Internet]. [cited 2017May 17]. Available from:http://www.theriaque.org/apps/contenu/accueil.php
- 10.Truven Health Products: Please Login [Internet]. [cited 2017May 17]. Available from:https://www.micromedexsolutions.com/home/dispatch
- 11.Interactions médicamenteuses - ANSM: Agence nationale de sécurité du médicament et des produits de santé [Internet]. [cited 2017May 17]. Available from:http://ansm.sante.fr/Dossiers/Interactions-medicamenteuses/Interactions-medicamenteuses/(offset)/0
- 12.Jaccard P (1907) La distribution de la flore dans la zone alpine. Vol. 18. 961 pGoogle Scholar
- 14.UCSF-FDA TransPortal [Internet]. [cited 2017May 17]. Available from:http://transportal.compbio.ucsf.edu/
- 15.DrugBank [Internet]. [cited 2017 Jan13];Available from: https://www.drugbank.ca/
- 23.Fernández de Palencia Espinosa MÁ, Díaz Carrasco MS, Alonso Romero JL, de la Rubia Nieto A, Espuny Miró A (2015) Potential drug-drug interactions in oncological adult inpatients at a Spanish hospital: epidemiology and risk factors. Int J Clin Pharm 37(6):1021–1027. https://doi.org/10.1007/s11096-015-0195-z CrossRefPubMedGoogle Scholar
- 27.Wiggins BS, Saseen JJ, Page RL, Reed BN, Sneed K, Kostis JB et al (2016) Recommendations for Management of Clinically Significant Drug-Drug Interactions with Statins and Select Agents Used in patients with cardiovascular disease: ascientific statement from the American Heart Association. Circulation 134(21):e468–e495. https://doi.org/10.1161/CIR.0000000000000456 CrossRefPubMedGoogle Scholar
- 29.Scheife RT, Hines LE, Boyce RD, Chung SP, Momper JD, Sommer CD, Abernethy DR, Horn JR, Sklar SJ, Wong SK, Jones G, Brown ML, Grizzle AJ, Comes S, Wilkins TL, Borst C, Wittie MA, Malone DC (2015) Consensus recommendations for systematic evaluation of drug-drug interaction evidence for clinical decision support. Drug Saf 38(2):197–206. https://doi.org/10.1007/s40264-014-0262-8 CrossRefPubMedPubMedCentralGoogle Scholar